Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 3 min ago
Peer-reviewedCC BY 4.0MedComm

Inhaled Nanomedicines for Lung Diseases and Injuries: Pharmacological Advances and Clinical Translation

  • Kajal Kamra1
  • Sonal Gaur2
  • Jaswinder Singh3
  1. 1Department of Pharmaceutical Sciences University of Nebraska Medical Center Omaha Nebraska USA
  2. 2Department of Ophthalmology Medical University of South Carolina Charleston South Carolina USA
  3. 3Department of Emergency Medicine University of Nebraska Medical Center Omaha Nebraska USA
Read full textPDFDOICite

Abstract

Respiratory diseases remain major causes of morbidity and mortality; however, inadequate pulmonary drug exposure and systemic toxicity continue to limit treatment efficacy. Inhaled nanomedicines offer opportunities for localized, sustained, and targeted therapy. This review examines how disease biology informs pulmonary delivery design across pulmonary fibrosis, lung cancer, chronic obstructive pulmonary disease, pulmonary infections, and acute lung injury/acute respiratory distress syndrome. It outlines anatomical and biological barriers and compares liposomes, lipid nanoparticles, polymeric and hybrid systems, biomimetic carriers, and stimuli‐responsive formulations. Particular attention is given to matching therapeutic cargo and carrier properties to fibroblasts, macrophages, tumor cells, and alveolar type II cells. Emerging approaches include mRNA delivery, siRNA‐mediated gene silencing, antisense oligonucleotides, and CRISPR‐based editing, alongside alveolar regeneration and biomarker‐guided treatment. These strategies are evaluated in relation to their delivery requirements and stage of development. The review also addresses aerosol‐device compatibility, manufacturing, repeated‐dose safety, regulatory considerations, and clinical outcomes. By connecting delivery mechanisms with disease‐specific applications and clinical evidence, this review identifies both therapeutic opportunities and barriers to translation. This integrated perspective can guide the development of inhaled nanomedicines with more reproducible pulmonary delivery, improved treatment efficacy, and acceptable safety.

Related

  1. Recent advances in the pharmacological effects and mechanisms of borneol and borneol-containing formulations in central nervous system diseases
    Xifang Zhang, Yijun Wu, Jin Han +4
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyCrossref
  2. Comparative policy analysis of national frameworks for the prevention of non-communicable diseases and injuries in children and adolescents
    Alireza Shoghli, Alireza Raeisi, Jafar Jandaghi +5
    BMC Public HealthPeer-reviewedCC BY-NC-ND 4.0Epidemiology & public healthCrossref
  3. Research Trends, Knowledge Evolution and Pharmacological Advances of Cordyceps cicadae: A Bibliometric Analysis
    Siyu Du, Ruyue Luo, Anqi Liu +3
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Pharmacology & toxicologyCrossref
  4. Pigeonpea leaves in orthopedic diseases: bioactive metabolites, pharmacological actions and therapeutic potential
    Yuan Zeng, Weifeng Liang, Jiayi Chen +6
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossrefEurope PMC
  5. [Mechanisms and Clinical Translation Advances of Physical Targeted Therapy for Malignant Pleural Effusion].
    Jia Zhao, Zhenyu Yin, Xin Hua
    Zhongguo fei ai za zhi = Chinese journal of lung cancerPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{kamra2026inhaled,
  title = {{Inhaled Nanomedicines for Lung Diseases and Injuries: Pharmacological Advances and Clinical Translation}},
  author = {Kajal Kamra and Sonal Gaur and Jaswinder Singh},
  journal = {MedComm},
  year = {2026},
  month = nov,
  doi = {10.1002/mco2.71047},
  url = {https://doi.org/10.1002/mco2.71047},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Inhaled Nanomedicines for Lung Diseases and Injuries: Pharmacological Advances and Clinical Translation
AU  - Kajal Kamra
AU  - Sonal Gaur
AU  - Jaswinder Singh
PY  - 2026
DA  - 2026/11/04
JO  - MedComm
DO  - 10.1002/mco2.71047
UR  - https://doi.org/10.1002/mco2.71047
AB  - Respiratory diseases remain major causes of morbidity and mortality; however, inadequate pulmonary drug exposure and systemic toxicity continue to limit treatment efficacy. Inhaled nanomedicines offer opportunities for localized, sustained, and targeted therapy. This review examines how disease biology informs pulmonary delivery design across pulmonary fibrosis, lung cancer, chronic obstructive pulmonary disease, pulmonary infections, and acute lung injury/acute respiratory distress syndrome. It outlines anatomical and biological barriers and compares liposomes, lipid nanoparticles, polymeric and hybrid systems, biomimetic carriers, and stimuli‐responsive formulations. Particular attention is given to matching therapeutic cargo and carrier properties to fibroblasts, macrophages, tumor cells, and alveolar type II cells. Emerging approaches include mRNA delivery, siRNA‐mediated gene silencing, antisense oligonucleotides, and CRISPR‐based editing, alongside alveolar regeneration and biomarker‐guided treatment. These strategies are evaluated in relation to their delivery requirements and stage of development. The review also addresses aerosol‐device compatibility, manufacturing, repeated‐dose safety, regulatory considerations, and clinical outcomes. By connecting delivery mechanisms with disease‐specific applications and clinical evidence, this review identifies both therapeutic opportunities and barriers to translation. This integrated perspective can guide the development of inhaled nanomedicines with more reproducible pulmonary delivery, improved treatment efficacy, and acceptable safety.
SN  - 2688-2663
ER  -